To Test the Effect of Selected Fibres and Flours in Flat Bread on Post-Prandial Blood Glucose and Insulin Responses in Healthy Indian Population
Not Applicable
Completed
- Conditions
- Healthy
- Registration Number
- NCT02814357
- Lead Sponsor
- Unilever R&D
- Brief Summary
Double-blind, randomized, controlled, cross-over design with 3 test products and one control product.
To evaluate the effect of 4 different flour compositions (guar gum 2% and 4%, chickpea flour 15% and barley flour 2% and 5%) of selected fibres and flours, on post-prandial plasma (PPG) and serum insulin levels in healthy Indian subjects, after the consumption of flat bread made from 100 gram of flour compositions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Healthy male and female subjects between > 20 and < 50 years of age
- BMI of >18 and < 23 kg/m2
- Fasting blood glucose value of volunteer is > 3.4 and <6.1 mmol/litre (i.e. 62- 110 mg/dl) at screening
Exclusion Criteria
- Chronic smokers, tobacco chewers and drinkers.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Positive incremental area under blood glucose curve 0-120 minutes
- Secondary Outcome Measures
Name Time Method Total area under the serum insulin curve 0-120 minutes
Trial Locations
- Locations (1)
Lambda Therapeutics Research Ltd (LTRL)
🇮🇳Ahmedabad, Near Gujrat High Court, SG Highway, Gota, India
Lambda Therapeutics Research Ltd (LTRL)🇮🇳Ahmedabad, Near Gujrat High Court, SG Highway, Gota, India